Condition
Primary Open Angle Glaucoma of Both Eyes
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownQlaris Phase 2 Study of QLS-111 in POAG And/or OHT PatientsNCT06016972 · 2024-03-05
COMPLETEDGlaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment DeviceNCT04595227 · 2020-10-30
UNKNOWNIs the Reduction in IOP After Treatment of 180 Degrees Equivalent to Treatment of 360 Degrees With SLT?NCT03529591 · 2018-06-29
COMPLETEDComparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mLNCT05973318 · 2017-04-10
COMPLETEDComparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/mlNCT05973305 · 2017-04-05
COMPLETEDCommon interventions
Computerized pupillary light reflex assessment deviceDEVICE1Cosopt eye drops, 20 mg/mL + 5 mg/mLDRUG1Dorzol 20 mg/mlDRUG1Dorzotimol eye drops, 20 mg/mL + 5 mg/mLDRUG1Experimental: QLS-111 ophthalmic solution, (0.015%)DRUG1Experimental: QLS-111 ophthalmic solution, (0.03%)DRUG1Experimental: QLS-111 ophthalmic solution, (0.075%)DRUG1QLS-111 ophthalmic vehicle solutionOTHER1Selective laser trabeculoplastyPROCEDURE1Selective laser trabeculoplasty (SLT)DEVICE1Trusopt 20 mg/mlDRUG1
Leading sponsors
Trial status mix
COMPLETED4
UNKNOWN1
Phase mix
PHASE32
NA1
PHASE21
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.